SCHEMBL4966627

SCHEMBL4966627

Cc1ccc(-c2ccc(C)c(C(=O)O)c2)cc1

nearest known ligand 0.70

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MCL1 Q07820 5/20 0.70
AKR1C2 P52895 1/20 0.57
AKR1C1 Q04828 1/20 0.57
ACMSD Q8TDX5 3/20 0.48
HNF4A P41235 2/20 0.48
DHFR P00374 1/20 0.48
KMT2A Q03164 2/20 0.48
KDM4E B2RXH2 1/20 0.48
GFER P55789 1/20 0.48
RXFP1 Q9HBX9 1/20 0.48
SMN1; SMN2 Q16637 2/20 0.47
CSNK2A1 P68400 1/20 0.47
CFD P00746 1/20 0.46
RXRB P28702 2/20 0.46
RXRA P19793 1/20 0.46
DHODH Q02127 1/20 0.45
ALDH1A1 P00352 1/20 0.45
MEN1 O00255 1/20 0.44
FTO Q9C0B1 1/20 0.44
EGLN1 Q9GZT9 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL70164 0.92 MCL1 (0.66) MCL1AKR1C2AKR1C1ACMSDHNF4A
Hydrochloric Acid SCHEMBL9153007 0.90 MCL1 (0.63) MCL1AKR1C2AKR1C1ACMSDHNF4A
SCHEMBL10024279 0.88 MCL1 (0.63) MCL1AKR1C2AKR1C1ACMSDHNF4A
SCHEMBL5255978 0.88 MCL1 (0.63) MCL1AKR1C2AKR1C1ACMSDHNF4A
SCHEMBL10024268 0.86 MCL1 (0.61) MCL1AKR1C2AKR1C1ACMSDHNF4A
SCHEMBL16351974 0.86 MCL1 (0.72) MCL1AKR1C2AKR1C1ACMSDHNF4A
SCHEMBL10024251 0.85 MCL1 (0.54) MCL1AKR1C2AKR1C1ACMSDHNF4A
SCHEMBL7326903 0.85 MCL1 (0.54) MCL1AKR1C2AKR1C1ACMSDHNF4A
SCHEMBL8840571 0.84 MCL1 (0.65) MCL1AKR1C2AKR1C1ACMSDHNF4A
SCHEMBL9154339 0.84 MCL1 (0.62) MCL1ACMSDHNF4ADHFRKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9793483-B2 Hexafluoroisopropanol group-containing diamine, polyimide and polyamide using same, cyclized product thereof, and method for producing same CENTRAL GLASS COMPANY, LIMITED (JP) 2017-10-17 US disclosed
US-20140148571-A1 Hexafluoroisopropanol Group-Containing Diamine, Polyimide And Polyamide Using Same, Cyclized Product Thereof, And Method For Producing Same CENTRAL GLASS COMPANY, LIMITED (JP) 2014-05-29 US disclosed
US-8496835-B2 Anion-exchange displacement chromatography process and anionic organic compounds for use as displacer compounds in anion-exchange displacement chromatography process SACHEM, INC. (US) 2013-07-30 US disclosed
US-20120083471-A1 Novel Compounds, Pharmaceutical Compositions Containing Same, Methods of Use for Same, and Methods for Preparing Same FAS SECURED CREDITORS HOLDCO, LLC 2012-04-05 US disclosed
EP-1960078-A2 ANION-EXCHANGE DISPLACEMENT CHROMATOGRAPHY PROCESS AND ANIONIC ORGANIC COMPOUNDS FOR USE AS DISPLACER COMPOUNDS IN ANION-EXCHANGE DISPLACEMENT CHROMATOGRAPHY PROCESS Sachem, Inc. (US) 2008-08-27 EP disclosed
WO-2007064809-A2 ANION-EXCHANGE DISPLACEMENT CHROMATOGRAPHY PROCESS AND ANIONIC ORGANIC COMPOUNDS FOR USE AS DISPLACER COMPOUNDS IN ANION-EXCHANGE DISPLACEMENT CHROMATOGRAPHY PROCESS SACHEM, INC. (US) 2007-06-07 WO disclosed
US-20070125712-A1 ANION-EXCHANGE DISPLACEMENT CHROMATOGRAPHY PROCESS AND ANIONIC ORGANIC COMPOUNDS FOR USE AS DISPLACER COMPOUNDS IN ANION-EXCHANGE DISPLACEMENT CHROMATOGRAPHY PROCESS PNC BANK, NATIONAL ASSOCIATION 2007-06-07 US disclosed
US-5545645-A Heterocyclic derivatives in the treatment of ischaemia and related diseases SYNTEX PHARMACEUTICALS, LIMITED (GB) 1996-08-13 US disclosed
EP-0719091-A1 NATURAL TRIGLYCERIDE FATS UNILEVER PLC (GB) 1996-07-03 EP disclosed
EP-0693062-A1 HETEROCYCLIC DERIVATIVES IN THE TREATMENT OF ISCHAEMIA AND RELATED DISEASES SYNTEX PHARMACEUTICALS LTD. (GB) 1996-01-24 EP disclosed
US-5428037-A Piperazine derivatives; calcium and sodium channel antagonists SYNTEX PHARMACEUTICALS, LTD. (GB) 1995-06-27 US disclosed
WO-1995007620-A1 NATURAL TRIGLYCERIDE FATS UNILEVER N.V. (NL) 1995-03-23 WO disclosed
WO-1994024116-A1 HETEROCYCLIC DERIVATIVES IN THE TREATMENT OF ISCHAEMIA AND RELATED DISEASES SYNTEX PHARMACEUTICALS LIMITED (GB) 1994-10-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120083471-A1 Novel Compounds, Pharmaceutical Compositions Containing Same, Methods of Use for Same, and Methods for Preparing Same LCAT, DGAT2, SOAT2 MCL1 4030/4885AKR1C2 848/4885AKR1C1 995/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.